Decibel Therapeutics - DBTX Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $5.25
  • Forecasted Upside: 6.92%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$4.91
▼ -0.04 (-0.81%)
Get New Decibel Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DBTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DBTX

Analyst Price Target is $5.25
▲ +6.92% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Decibel Therapeutics in the last 3 months. The average price target is $5.25, with a high forecast of $5.25 and a low forecast of $5.25. The average price target represents a 6.92% upside from the last price of $4.91.

This chart shows the closing price for DBTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 2 polled investment analysts is to hold stock in Decibel Therapeutics. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/29/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/27/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/27/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/22/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/22/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/21/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/10/2023Robert W. BairdDowngradeOutperform ➝ Neutral$21.00 ➝ $5.25Low
8/9/2023HC WainwrightDowngradeBuy ➝ NeutralLow
3/15/2023SVB LeerinkDowngradeOutperform ➝ Market Perform$7.00 ➝ $2.00Low
3/15/2023HC WainwrightReiterated RatingBuy$23.00Low
3/15/2023SVB SecuritiesDowngradeOutperform ➝ Market Perform$7.00 ➝ $2.00Low
2/13/2023HC WainwrightReiterated RatingBuy$23.00N/A
1/23/2023SVB LeerinkLower TargetOutperform$10.00 ➝ $7.00Low
11/10/2022CitigroupLower TargetBuy$12.00 ➝ $10.00Low
9/21/2022HC WainwrightReiterated RatingBuy$23.00Low
8/11/2022HC WainwrightReiterated RatingBuyLow
6/9/2022HC WainwrightReiterated RatingBuy$23.00Low
5/17/2022CitigroupLower TargetBuy$20.00 ➝ $15.00N/A
3/21/2022BarclaysLower TargetOverweight$30.00 ➝ $7.00High
12/2/2021JonestradingInitiated CoverageBuy$25.00Medium
11/15/2021HC WainwrightInitiated CoverageBuy$23.00Medium
11/11/2021CitigroupLower TargetBuy$29.00 ➝ $20.00Low
11/10/2021SVB LeerinkLower TargetOutperform$15.00 ➝ $14.00Low
10/21/2021Robert W. BairdInitiated CoverageOutperform$21.00High
8/11/2021BMO Capital MarketsLower TargetOutperform$27.00 ➝ $24.00High
5/31/2021SVB LeerinkReiterated RatingBuyHigh
5/14/2021SVB LeerinkLower TargetOutperform$26.00 ➝ $18.00High
3/9/2021CitigroupInitiated CoverageBuy$29.00High
3/9/2021SVB LeerinkInitiated CoverageOutperform$26.00High
3/9/2021BMO Capital MarketsInitiated CoverageOutperform$30.00High
3/9/2021BarclaysInitiated CoverageOverweight$30.00High
(Data available from 4/21/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/24/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/24/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/23/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/23/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/22/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/22/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/21/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Decibel Therapeutics logo
Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. The company's product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. Its lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene. The company is also developing DB-ATO and AAV.201, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy by regenerating lost hair cells within the vestibule; DB-020 for the prevention of cisplatin-induced hearing loss, which is in Phase 1b clinical trial; AAV.103 to restore hearing in individuals with a gap junction beta-2 (GJB2) deficiency; AAV.104 to restore hearing in individuals with stereocilin (STRC) deficiency; and cochlear hair cell regeneration program, an AAV-based gene therapy that utilizes cell-selective expression of reprogramming factors to convert supporting cells into outer hair cells. Decibel Therapeutics, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop gene therapies for monogenic forms of congenital hearing loss. The company was formerly known as Hearing Inc. and changed its name to Decibel Therapeutics, Inc. in April 2014. Decibel Therapeutics, Inc. was incorporated in 2013 and is headquartered in Boston, Massachusetts. As of September 25, 2023, Decibel Therapeutics, Inc. operates as a subsidiary of Regeneron Pharmaceuticals, Inc.
Read More

Today's Range

Now: $4.91
Low: $4.90
High: $5.11

50 Day Range

MA: $5.00
Low: $4.91
High: $5.23

52 Week Range

Now: $4.91
Low: $1.61
High: $5.40

Volume

1,261,100 shs

Average Volume

122,002 shs

Market Capitalization

$123.39 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Decibel Therapeutics?

The following equities research analysts have issued reports on Decibel Therapeutics in the last twelve months: HC Wainwright, and Robert W. Baird.
View the latest analyst ratings for DBTX.

What is the current price target for Decibel Therapeutics?

1 Wall Street analysts have set twelve-month price targets for Decibel Therapeutics in the last year. Their average twelve-month price target is $5.25, suggesting a possible upside of 6.9%. Robert W. Baird has the highest price target set, predicting DBTX will reach $5.25 in the next twelve months. Robert W. Baird has the lowest price target set, forecasting a price of $5.25 for Decibel Therapeutics in the next year.
View the latest price targets for DBTX.

What is the current consensus analyst rating for Decibel Therapeutics?

Decibel Therapeutics currently has 2 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in DBTX, but not buy more shares or sell existing shares.
View the latest ratings for DBTX.

What other companies compete with Decibel Therapeutics?

How do I contact Decibel Therapeutics' investor relations team?

Decibel Therapeutics' physical mailing address is 1325 Boylston Street Suite 500, Boston MA, 02215. The company's listed phone number is 617-370-8701 and its investor relations email address is [email protected]. The official website for Decibel Therapeutics is decibeltx.com. Learn More about contacing Decibel Therapeutics investor relations.